Bitcoin Holds Near $62,700 as Rate Fears and ETF Outflows Mount
The world's largest cryptocurrency traded flat as investors grappled with geopolitical tensions, the prospect of higher interest rates, and persistent selling from institutional funds.
Latest by TrustFinance Global Insights
Iran Claims Strike on US Base in Jordan as US Reinstates Naval Blockade
Iran's IRGC said it fired ballistic missiles at a U.S. air base in Jordan, while the U.S. completed a third night of air strikes and reimposed a naval blockade, sending oil prices up nearly 3%.
BMW Sales Plunge in China as Automaker Struggles to Keep Pace with Local EV Rivals
The German automaker reported a 30% drop in second-quarter China sales and issued a recent profit warning, highlighting its challenges in a market increasingly dominated by fast-moving domestic EV brands.
Australian Lithium Stocks Decline as Weaker Prices in China Pressure Sector
Shares of Australian lithium producers fell broadly on Tuesday, pressured by a drop in Chinese lithium carbonate futures amid concerns over rising supply and moderating near-term demand.
ASML Earnings: Investors Eye Capacity and China Export Curbs Amid AI Boom
Semiconductor equipment giant ASML is set to report earnings, with markets focused on its ability to meet soaring AI-driven demand and navigate geopolitical headwinds from U.S. export controls on China.
Taiwan Weighted Index Ends Flat as Old Economy Gains Offset Tech Weakness
Taiwan's benchmark stock index closed with a marginal gain on Tuesday, as strength in the plastics and energy sectors was largely canceled out by steep declines in select technology stocks.
XVIVO Q2 Sales Rise 34%, Beating Estimates on Thoracic Segment Strength
Swedish medical technology company XVIVO reported second-quarter net sales that surpassed analyst expectations, driven by a 53% surge in its thoracic organ transplant division.
AstraZeneca Inks $1.5 Billion Deal for Global Rights to Dizal's Lung Cancer Treatment
AstraZeneca will pay Dizal Pharmaceutical an upfront sum of $600 million for the global rights to its lung cancer drug, Sunvozertinib, with the total deal value potentially reaching $1.5 billion.
AQ Group Lifts Profit Margin Target After Q2 Sales Beat Analyst Estimates
Swedish industrial components maker AQ Group raised its pretax profit margin target to 10% from 8% after reporting second-quarter net sales of SEK 2.58 billion, exceeding analyst expectations.